Abstract

Biography

Sven Van den Berghe is CEO of PanTera, a spin-off company of SCK CEN and IBA developing an industrial production facility for actinium-225 (Ac-225) to help scale targeted alpha therapies for cancer treatment.

With a Master's degree in Physics from Ghent University and a PhD in Materials Science from the University of Limoges, in collaboration with the Institute for Transuranic Elements and SCK CEN, he has built a deep expertise in nuclear fuels and materials—particularly research-reactor fuel qualification, fuel microstructural evolution under irradiation, Molybdenum-99 production target development, and HEU-to-LEU conversion including high-density LEU fuels for high-performance research reactors. He previously held senior roles at SCK CEN, including BR2 reactor stakeholder manager and Director of the Institute for Nuclear Materials Science (NMS), which hosts the BR2 research reactor and hot-laboratory infrastructure. In that capacity, he also managed the commercial side of medical radioisotope production at SCK CEN, including Molybdenum-99 and Lutetium-177.